We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

85 hedge funds and large institutions have $137M invested in UroGen Pharma in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

31% more funds holding

Funds holding: 65 → 85 (+20)

18% more capital invested

Capital invested by funds: $116M → $137M (+$20.7M)

2.92% more ownership

Funds ownership: 53.41% → 56.33% (+2.9%)

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

36% less call options, than puts

Call options by funds: $193K | Put options by funds: $300K

Holders
85
Holders Change
+20
Holders Change %
+30.77%
% of All Funds
1.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
15
Reduced
20
Closed
10
Calls
$193K
Puts
$300K
Net Calls
-$107K
Net Calls Change
-$876K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.97M
2
State Street
State Street
Massachusetts
+$3.3M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.07M
4
Northern Trust
Northern Trust
Illinois
+$1.74M
5
AA
AlphaCentric Advisors
Puerto Rico
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
-$4.29M
2
SCM
Stonepine Capital Management
Oregon
-$2.79M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.06M
4
Millennium Management
Millennium Management
New York
-$1.79M
5
Bank of America
Bank of America
North Carolina
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
26
Eversept Partners
New York
$774K +$825K +74,797 New
Renaissance Technologies
27
Renaissance Technologies
New York
$766K +$287K +26,000 +54%
Morgan Stanley
28
Morgan Stanley
New York
$652K -$888K -80,506 -56%
N
29
Nuveen
North Carolina
$636K +$678K +61,462 New
JP Morgan Chase
30
JP Morgan Chase
New York
$530K -$101K -9,174 -15%
Citadel Advisors
31
Citadel Advisors
Florida
$497K -$322K -29,196 -38%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$475K +$507K +45,920 New
Charles Schwab
33
Charles Schwab
California
$463K +$493K +44,724 New
CBA
34
Coastal Bridge Advisors
Connecticut
$391K +$8.08K +732 +2%
BRA
35
Bender Robert & Associates
California
$359K – – –
Simplex Trading
36
Simplex Trading
Illinois
$355K -$6.86K -622 -2%
SAM
37
Shikiar Asset Management
New York
$344K – – –
Bank of America
38
Bank of America
North Carolina
$327K -$1.09M -99,036 -76%
Goldman Sachs
39
Goldman Sachs
New York
$325K -$432K -39,172 -56%
BP
40
BBR Partners
New York
$269K – – –
PAI
41
Palo Alto Investors
California
$254K – – –
XT
42
XTX Topco
Cayman Islands
$241K +$257K +23,323 New
KHLMTHM
43
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$235K – – –
Connor, Clark & Lunn Investment Management (CC&L)
44
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$223K +$237K +21,506 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$211K +$225K +20,406 New
Two Sigma Investments
46
Two Sigma Investments
New York
$205K +$219K +19,815 New
DA
47
Denali Advisors
California
$197K +$210K +19,000 New
CAM
48
Cresset Asset Management
Illinois
$178K +$190K +17,193 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$168K +$4.7K +426 +3%
PCIG
50
Partners Capital Investment Group
Massachusetts
$159K +$170K +15,384 New
1
2
3 4

URGN Hedge Fund Activity: Q2 2023 in Review

85 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2023, worth a combined $137M — up 18% from $116M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new URGN positions and 10 closed out — a net gain of 20 holders — while 15 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $8.97M. The largest seller was Menora Mivtachim Holdings, cutting an estimated $4.29M.

  • 85 institutional investors held UroGen Pharma (URGN) as of Q2 2023, up from 65 in Q1 2023.
  • Funds reported $137M of UroGen Pharma stock for Q2 2023, up 18% quarter-over-quarter.
  • 30 funds opened new UroGen Pharma positions in Q2 2023 and 10 closed out, a net change of +20 holders.
  • The largest UroGen Pharma buyer in Q2 2023 was BlackRock, an estimated $8.97M added.
  • The largest UroGen Pharma seller in Q2 2023 was Menora Mivtachim Holdings, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2023.